Janus Henderson Group PLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janus Henderson Group PLC reduced its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 96.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,319 shares of the company’s stock after selling 675,069 shares during the quarter. Janus Henderson Group PLC owned about 0.05% of Pacira BioSciences worth $351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Centiva Capital LP bought a new stake in Pacira BioSciences during the third quarter worth about $398,000. PDT Partners LLC purchased a new position in shares of Pacira BioSciences during the 3rd quarter valued at about $3,469,000. Verition Fund Management LLC bought a new stake in Pacira BioSciences in the 3rd quarter worth approximately $493,000. FORA Capital LLC bought a new stake in Pacira BioSciences in the 3rd quarter worth approximately $431,000. Finally, BNP Paribas Financial Markets boosted its stake in Pacira BioSciences by 269.7% in the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares in the last quarter. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Stock Performance

PCRX opened at $19.86 on Monday. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a 50 day simple moving average of $17.27 and a two-hundred day simple moving average of $19.04.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada boosted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Jefferies Financial Group raised their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th. Finally, Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.